Immunophenotypic changes in juvenile myelomonocytic leukaemia after treatment with hypomethylating agent: Do they help to evaluate dept of response?

• Published in: British journal of haematology Vol. 197; no. 3; pp. 339 - 348
• Main Authors: Oliveira, Anita Frisanco, Tansini, Aline, Toledo, Thais, Balceiro, Rafael, Lee, Maria Lucia Martino, Villela, Neysimelia, Ikeuty, Patricia, Metze, Konradin, Lopes, Luiz Fernando, Lorand‐Metze, Irene
• Format: Journal Article
• Language: English
• Published: Oxford Blackwell Publishing Ltd 01.05.2022
• Subjects: azacytidine; CD34 antigen; CD7 antigen; Diagnosis; Hematology; immunophenotyping; juvenile myelomonocytic leukaemia; Leukemia; Lymphocytes T; Monocytes; Myelomonocytic leukemia; Patients; Progenitor cells; Stem cell transplantation; treatment
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.18089

Summary 5‐Azacitidine has been used before stem cell transplantation in juvenile myelomonocytic leukaemia (JMML) patients. Recently, we have described immunophenotypic features in JMML at diagnosis. Here, our aim was to examine the changes in the immunophenotypic features during azacitidine treatment, correlating it with clinical response. Patients treated with 5‐azacitidine were evaluated at diagnosis and after three and six cycles of medication. Among 32 patients entering the study, 28 patients were examined after three cycles and 25 patients after six. Patients showed a reduction in CD34/CD117+ cells: median 3.35% at diagnosis, 2.8% after three cycles and 1.63% after six. B‐cell progenitors were decreased at diagnosis and decreased after treatment. Monocytes decreased: 11.91% to 6.4% and 4.18% respectively. Complete response was associated with increase in classical monocytes. T lymphocytes, reduced at diagnosis, increased in patients responding to 5‐azacitidine. Immunophenotypic aberrancies including expression of CD7 in myeloid progenitors remained after treatment. This feature was associated with a worse response to treatment, as well as presence of NF1. Immunophenotyping was feasible in all patients. Clinical response was associated with a decrease of myeloid progenitors and monocytes and a rise in T lymphocytes although phenotypic aberrancies persisted. The largest effect was observed after three cycles.